What is Gravity Diagnostics?
Gravity Diagnostics operates as a premier, CAP-accredited and CLIA-certified laboratory, offering a diverse suite of testing services including toxicology, pharmacogenetics, and infectious disease screening. The company distinguishes itself through a commitment to regulatory excellence and clinical integrity, serving as a vital partner for physicians and healthcare systems. By leveraging advanced diagnostic methodologies, Gravity Diagnostics addresses the evolving needs of the medical community, ensuring rapid and accurate results that facilitate improved patient outcomes. Its operational model is built upon a foundation of compliance and technical expertise, allowing it to navigate the complexities of the healthcare regulatory environment while maintaining high-throughput testing capabilities.
How much funding has Gravity Diagnostics raised?
Gravity Diagnostics has raised a total of $5.3M across 2 funding rounds:
Debt
$350K
Other Financing Round
$5M
Debt (2020): $350K with participation from PPP
Other Financing Round (2025): $5M led by The Community Development Venture Capital Alliance and Advantage Capital
Key Investors in Gravity Diagnostics
The Community Development Venture Capital Alliance
The Community Development Venture Capital Alliance (CDVCA) is a network dedicated to the community development venture capital (CDVC) industry, providing flexible equity risk capital to businesses in low-income communities.
Advantage Capital
Advantage Capital Partners operates as a venture capital firm investing in cleantech, communication, energy, information technology, and life sciences industries.
PPP
Public-Private Partnership
What's next for Gravity Diagnostics?
With the successful closure of this major strategic investment, Gravity Diagnostics is poised to prioritize the expansion of its diagnostic portfolio and the optimization of its laboratory workflows. The capital will likely be deployed to integrate next-generation sequencing technologies and enhance the firm's digital health interface, further streamlining the physician-patient diagnostic journey. As the company scales, it remains focused on maintaining its rigorous standards of clinical accuracy while exploring new market segments in personalized medicine and preventative health. This strategic growth phase is expected to solidify the company's reputation as a leader in the diagnostic space, fostering long-term value creation for its stakeholders and the broader healthcare ecosystem.
See full Gravity Diagnostics company page
